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Background: Accelerated reproductive aging, in women indicated by early natural menopause, 119 
is associated with an increased risk of coronary heart disease (CHD) in observational studies. 120 
Genomic variants for age at natural menopause (ANM) have been implicated in genome 121 
stability, immune function and mitochondrial biogenesis, which are not sex-specific processes. 122 
We aimed to establish the causal association between reproductive aging and (non-)fatal CHD 123 
and CHD risk factors using ANM variants as a measure for genetically determined reproductive 124 
aging in women and in men, since genome-wide association studies (GWAS) for reproductive 125 
aging traits in men are lacking.  126 
Methods: We performed a 2-sample Mendelian Randomization (MR) using four methods: the 127 
simple median-based method, the weighted median-based method, the standard inverse-variance 128 
weighted (IVW) regression and the MR-Egger regression. Summary statistics were pooled from 129 
three studies with together 417,579 participants from European descent, including 49,150 CHD 130 
cases. Publicly available GWAS and EPIC-CVD were pooled for total cholesterol, high density 131 
lipoprotein cholesterol, triglycerides, HbA1c, and glucose.  132 
Results: Our MR analyses show no association between genetically determined reproductive 133 
aging and CHD risk in women (Relative Risk Estimate (RRE)IVW=0.99, 95% confidence interval 134 
(CI): 0.97;1.01), or any of the CHD risk factors. No associations were found in men.  135 
Conclusion: Reproductive aging is not causally associated with CHD risk or CHD risk factors in 136 
women, nor in men. The association between early menopause and CHD risk in observational 137 
studies might be the result of residual confounding, reverse causation, or reflect a shared 138 




Keywords: Reproductive aging, Mendelian randomization, coronary heart disease, 141 
cardiovascular risk factors 142 
 143 
Key messages: 144 
 Genetically determined reproductive aging is not associated with coronary heart disease 145 
in women.  146 
 Genetically determined reproductive aging is not associated with coronary heart disease 147 
in men, although the validity of the genetic instrument is not established in men.  148 
 Genetically determined reproductive aging is not associated with cardiovascular risk 149 
factors (total cholesterol, high density lipoprotein cholesterol, triglycerides, 150 
apolipoprotein A1, apolipoprotein B, C-reactive protein, glucose and HbA1c).  151 
  152 
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Introduction   153 
Cardiovascular disease (CVD) is the leading cause of death in both men and women(1). 154 
Accelerated reproductive aging, as indicated by early menopause in women, has been associated 155 
with increased risk of CVD(2–5). The mechanisms underlying these associations are not fully 156 
understood yet; deterioration of traditional CVD risk factors, in particular cholesterol, has been 157 
suggested to play a role(6,7). Although men do not experience an abrupt start or stop of their 158 
reproductive period, there is limited evidence that in men reproductive functions, such as erectile 159 
dysfunction, sperm motility and morphology, and semen volume, also decline with aging(8–10). 160 
Some of these, e.g. erectile dysfunction and decreasing testosterone levels, sometimes referred to 161 
as andropause, have been associated with increased CVD risk as well(11,12). Since male 162 
reproductive aging is a gradual process into old age, it is more complicated to study health 163 
effects of accelerated reproductive aging in males.  164 
 In observational studies, it is difficult to disentangle the potential independent effect of 165 
accelerated reproductive aging on CVD risk from the effect of general aging, as residual 166 
confounding can still be present. Furthermore, reversed causality can also play a role here, as 167 
women with an unfavourable CVD risk profile have been reported to experience accelerated 168 
reproductive aging(13). Mendelian Randomization (MR) designs, exploiting the principle of 169 
random independent segregation of alleles at meiosis, are a means to establish causality in 170 
situations where randomized clinical trials are impossible(14,15). In MR studies, single 171 
nucleotide polymorphisms (SNPs) associated with the exposure as found in genome-wide 172 
association studies (GWAS) are used as instrumental variables. 173 
To date, GWAS have been conducted for the reproductive aging trait age at natural 174 
menopause (ANM) in women, while GWAS for male reproductive aging traits are not available. 175 
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The ANM GWAS reported 56 SNPs that are mainly implicated in genome stability (DNA 176 
repair), immune function and mitochondrial biogenesis(16). As these mechanisms are not 177 
specific for women, we hypothesized that these mechanisms underlie reproductive aging in men 178 
as well.  179 
A recent study in three cohorts suggested a harmful effect of ANM, genetically 180 
determined by the 56 SNPs, on CVD and CHD risk in women, but not in men. However, the 181 
sample size was small. Replication in a large sample size using publicly available data, 182 
conducted in women only, gave a null finding (17). This study did not investigate cardiovascular 183 
risk factors as an outcome.   184 
The aims of the present study are to establish the causal association between reproductive 185 
aging and fatal or non-fatal CHD, and to gain more insight in possible mechanisms underlying 186 
the association between genetically determined reproductive aging and cardiovascular risk 187 
factors in women, using 56 SNPs associated with earlier ANM. Furthermore, we aim to establish 188 
whether the same mechanisms are associated with CHD and traditional cardiovascular risk 189 
factors in men as well. We used the same 56 ANM variants as a measure for genetically 190 
determined reproductive aging in men, postulating common genetic mechanisms of reproductive 191 
aging. 192 




Study populations and outcomes 195 
Fatal or non-fatal CHD 196 
We used data from 417,579 participants of European descent (including 49,150 CHD cases) 197 
from three studies: the UK Biobank(18), a modified version of the CARDIoGRAMplusC4D 198 
consortium (m-CARDIoGRAMplusC4D) since we could only include those studies that 199 
provided us with sex-specific summary data (Cardiogenics, Thiseas, AMC-PAS, Duke 2, CCGB 200 
2, ITH 2, OHGS A2, OHGS B2, OHGS C2, Germifs I, Germifs II, Germifs III, Germifs IV, 201 
LIFE-Heart and LURIC(19)), and the EPIC-CVD case-cohort study(20). Details of the three 202 
studies (UK Biobank, m-CARDIoGRAMplusC4D and EPIC-CVD), including definitions of 203 
fatal or non-fatal CHD in each study, can be found in supplement 1.  204 
Traditional CHD risk factors 205 
For the associations between genetically determined reproductive aging and CHD risk factors, 206 
we again used data from EPIC-CVD and combined these with publicly available GWAS 207 
summary statistics of the Global Lipids Genetics Consortium(21) (total cholesterol, high density 208 
lipoprotein (HDL) cholesterol, triglycerides) and MAGIC(22,23) (HbA1c, fasting glucose). 209 
Details on these consortia can be found in supplement 1.We did not have access to sex-specific 210 
data for these risk factors. Therefore, we could only perform a pooled MR analyses for men and 211 
women combined.  212 
 213 
Genotyping and SNP selection 214 
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Genotyping in the UK Biobank was performed using the Affymetrix UK BiLEVE Axiom array 215 
and the Affymetrix UK Biobank Axiom Array(18,24). The m-CARDIoGRAMplusC4D studies 216 
have used various genotyping methods as described previously(19). EPIC-CVD participants 217 
were genotyped with the Human Core Exome array, Illumina 660 Quad array, and Omni Exome 218 
Express array. The Global Lipids Genetics Consortium and MAGIC also used different assays as 219 
described previously(21–23).   220 
 A recent genome-wide meta-analysis identified 56 SNPs associated with younger ANM 221 
among European descendants, 54 common HapMap SNPs and two Exome chip SNPs(16). All 222 
SNPs passed the threshold of p<5e-6, but not all the threshold of p<5e-8. No linkage 223 
disequilibrium (LD) at R
2
>0.9 was present among these 56 SNPs. Pleiotropic effects were 224 
investigated by searching the NHGRI-EBI GWAS Catalog(25) and Phenoscanner(26) for the 225 
SNPs or their proxies (R
2
>0.8). We used the 56 ANM variants as a measure for genetically 226 
determined reproductive aging in both women, and in men, since GWAS for reproductive aging 227 
traits in men are lacking. 228 
 229 
Statistical analyses  230 
We verified whether the ANM variants were a valid instrument for the MR analysis in women by 231 
calculating the F-statistic according to the method described previously(27), using the SD (5.8 232 
years) for ANM from the imputed data in the EPIC-CVD subcohort and the beta’s for the ANM 233 
variants from the GWAS(16).  234 
Regarding the outcome CHD, for UK Biobank and m-CARDIoGRAMplusC4D, odds 235 
ratios and standard errors for the SNP-CHD relations were derived through contact persons. For 236 
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EPIC-CVD, Prentice-weighted Cox proportional hazards regression adjusted for age, country, 237 
the first two principal components and array was used to calculate hazard ratios and standard 238 
errors for the EPIC-CVD case-cohort set. Regarding CHD risk factors, we derived effect 239 
estimates and standard errors for the cardiovascular risk factors (Global Lipids Genetics 240 
Consortium(21) for total cholesterol, HDL cholesterol and triglycerides, and MAGIC(22,23) for 241 
HbA1c and fasting glucose) using Phenoscanner(26). In the random subcohort of EPIC-CVD, we 242 
first imputed the missing observational data of EPIC-CVD (non-genetic data only) using 243 
multiple imputation with the MICE package in R(28) with 10 imputations and 50 iterations, 244 
including the CVD risk factors, SNPs and other baseline characteristics as predictors. 245 
Subsequently, we derived regression coefficients with linear regression in the subcohort only, 246 
separately in each imputation, using the same adjustments as for CHD. Thereafter we pooled the 247 
results with Rubin’s Rule(29).  248 
We performed a 2-sample MR using four separate methods to estimate causal effects for 249 
binary (CHD) and continuous (total cholesterol, HDL cholesterol, triglycerides, apolipoprotein A 250 
(apoA1), apolipoprotein B (apoB), C-reactive protein (CRP), glucose and HbA1c) outcomes: the 251 
simple median-based method, the weighted median-based method, the standard inverse-variance 252 
weighted (IVW) regression and the MR-Egger regression using the ‘Mendelian Randomization’ 253 
package in R(30). The IVW provides a consistent estimate and assumes that all assumptions of 254 
the instrumental variable are met, the median based and MR-Egger methods provide estimates 255 
under weaker assumptions, with the MR-Egger additionally providing an intercept that 256 
represents the average pleiotropic effect(31,32). When unbalanced horizontal pleiotropy is 257 
absent, results of all methods are expected to be consistent(33). We first conducted sex-specific 258 
MR analyses for CHD in all three studies (UK Biobank, m-CARDIoGRAMplusC4D, EPIC-259 
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CVD) separately. Subsequently, we pooled the estimates with a fixed effect model as is standard 260 
in MR studies. Similarly, MR analyses were performed for each cardiovascular risk factor in 261 
each study separately (EPIC-CVD, Global Lipids Genetics Consortium, MAGIC) and then 262 
pooled using a fixed effects model. Sex-specific analyses were possible in EPIC-CVD only, 263 
therefore we pooled the results for both sexes for combining with Global Lipids Genetics 264 
Consortium and MAGIC). All analyses were conducted with R version 3.2.0(34). 265 




Table 1 provides an overview of the numbers of cases and non-cases in UK Biobank, m-268 
CARDIoGRAMplusC4D, and EPIC-CVD.  269 
 270 
(Table 1 here) 271 
 272 
The F-statistic for genetically determined reproductive aging in women was 93.7. Table 2 shows 273 
the results for the association between genetically determined reproductive aging and CHD per 274 
MR method stratified by sex and by study (UKBiobank, m-CARDIoGRAMplusC4D, and EPIC-275 
CVD). In women, the IVW analyses in each study separately showed no causal association 276 
between genetically determined reproductive aging and CHD, nor when studies were pooled 277 
together (Relative Risk Estimate[RRE]IVW=0.99; 95% confidence interval [CI]=0.97;1.01). The 278 
MR-Egger method indicated no pleiotropic effects (intercept=0.004, p=0.318) and resulted in an 279 
RRE of 0.97 (95%CI=0.94;1.02) in the pooled data. Similar results were found for men with a 280 
pooled RREIVW of 1.00 (95%CI=0.97;1.02), also indicating no pleiotropic effects (RREMR-281 
Egger=1.00 (95%CI=0.95;1.05), intercept=0.000, p=0.948).  282 
 283 
(Table 2 here) 284 
 285 
Table 3 shows the IVW results for the association between genetically determined reproductive 286 
aging and cardiovascular risk factors, with sex-specific estimates only from the EPIC-CVD 287 
subcohort and the sex-combined pooled estimates from both publicly available GWAS data and 288 
the EPIC-CVD subcohort. For each one-year decrease in genetically determined reproductive 289 
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aging, total cholesterol levels decreased with 0.025 mmol/L in women in IVW-analysis, however 290 
this was not statistically significant (95%CI= -0.056;0.005). Similarly, genetically determined 291 
reproductive aging was not causally associated with total cholesterol in men (betaIVW=0.024 292 
mmol/L, 95%CI= -0.011;0.059), nor in the pooled sex-combined results (pooled betaIVW=-0.005 293 
mmol/L, 95%CI= -0.007;0.017). Again, no pleiotropic effects were detected (supplement 2). 294 
Furthermore, no causal association was found for HDL cholesterol, triglycerides, ApoA1, ApoB, 295 
CRP, glucose, and HbA1c (table 3).  296 
 297 
(Table 3 here) 298 
 299 




This study did not find a causal association between reproductive aging and CHD risk or CHD 302 
risk factors, including cholesterol levels, in women. Furthermore, this study does not provide 303 
evidence for a causal association between reproductive aging and CHD risk or CHD risk factors 304 
in men.  305 
 Strengths of this study are that, to the best of our knowledge, this is the largest MR study 306 
of associations between reproductive aging and CHD to date with 20,169 CHD events in women 307 
and 27,397 in men. We used several methods for MR analyses all yielding consistent results for 308 
the tested hypotheses, and in women the instrument we used was strong (F-statistic 93.7). Some 309 
limitations need to be acknowledged. First, we cannot establish whether the ANM risk score is a 310 
valid instrument for reproductive aging in men. The F-statistic is calculated using observed 311 
menopausal age in women, but men do not have a similar trait with an abrupt stop in 312 
reproductive potential. Since the SNPs we used are mainly implicated in mechanisms that are not 313 
specific for women, we hypothesized that there are common mechanisms of reproductive aging 314 
for women and men, and that, therefore, the same variants can be used as marker for genetically 315 
determined reproductive aging in men. However, it needs to be acknowledged that corresponding 316 
phenotypic traits in men need to be further investigated. Second, the GWAS on ANM included 317 
women with an ANM between 40 and 60 years only and therefore did not include women with 318 
an extremely early menopause (<40) or premature ovary insufficiency (POI). Most of the 319 
observational studies did include women with an extremely early menopause or POI, and two 320 
recent systematic reviews and meta-analyses of observational studies showed that POI is 321 
associated with both fatal and non-fatal CHD and CVD(35,36). Although we could not study an 322 
effect of extremely early menopause in our MR study, a recent GWAS on early menopause 323 
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revealed no new genetic variants for early menopause and showed that the genetic aetiology of 324 
early menopause overlaps with that of ANM. Thus early menopause is at least partly explained 325 
by the same polygenic variants as ANM(37). Third, our analyses with glucose were based on 326 
both fasting (MAGIC) and non-fasting estimates (EPIC-CVD). Although both are associated 327 
with an increased CVD risk(38,39) it might not be appropriate to combine them, since different 328 
SNPs might drive the association and underlying mechanisms could be different.   329 
 Our findings regarding CHD are partly in contrast with one previous study investigating 330 
the association between ANM SNPs and CHD death, which reported a significantly increased 331 
risk of CHD death with a weighted genetic risc score (wGRS) in women, but not in men(17). 332 
However, our findings are in line with those of the MR analysis in women, presented in the same 333 
paper, using CARDIoGRAMplusC4D data only, which was also null. The discrepancy between 334 
the wGRS and MR findings is potentially due to the fact that the wGRS analysis was adjusted for 335 
several known CVD risk factors (current smoking, body mass index, hypertension, type 2 336 
diabetes, total cholesterol, and lipid treatment). This might induce a biased association between 337 
the genetic variant and the outcome through confounder(s), also known as collider bias(40,41). 338 
In addition, the number of cases used for the wGRS analyses was small (only 541 CHD deaths in 339 
women), so a chance finding cannot be ruled out either. 340 
Our MR-study suggests that the association between genetically determined reproductive 341 
aging and CHD is not causal. However, most observational studies do find an association 342 
between early age at menopause and CHD in women. We suggest several explanations for this 343 
finding. First, observational studies are susceptible to residual confounding and reverse 344 
causation. It is possible that residual confounding is still present. Postmenopausal women are by 345 
definition older than premenopausal women, making it challenging to separate the effects of 346 
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biological aging from the various phases of the reproductive aging process.  Hence, residual 347 
confounding due to age may still be present in observational studies. Second, reverse causation is 348 
another potential problem in observational studies. Although most studies assume that an early 349 
ANM increases CHD risk, it might be possible that an unfavourable cardiovascular risk profile, 350 
or accelerated vascular aging, causes an early ANM. One previous study showed indeed that 351 
higher cholesterol levels prior to menopause were associated with earlier menopause(13). 352 
However, another study found no association between premenopausal CVD and subsequent age 353 
at menopause(42). If anything, women who developed CVD before menopause had a lower risk 354 
of becoming postmenopausal than women without premenopausal CVD (HR=0.98 for CVD and 355 
HR=0.90 for MI), indicating that menopause occurred later in these women(42), but none of 356 
these results were statistically significant due to the small number of premenopausal cases.  357 
MR uses SNPs, that are randomly assigned by birth, as instrumental variables, and as 358 
such provides a method to assess causality(43). However, an MR study makes several 359 
assumptions, that have to be taken into account(44). The first assumption is that the genetic 360 
marker is associated with the exposure. The SNPs used in our study were all associated with 361 
ANM at a p-value <5e-6 in the latest and largest GWAS(16) . As discussed above, this may not 362 
be true in men. The second and third assumptions are that the association between the genetic 363 
marker and the outcome is explained exclusively through the exposure of interest and is 364 
unconfounded. This is often referred to as the absence of pleiotropy, which means that the 365 
genetic variant is not associated with other phenotypes. Although our Phenoscanner search 366 
showed that a few of the SNPs are associated with age at menarche or sex hormone levels, and 367 
thus that some pleiotropy may be present, our MR-Egger analysis showed no indication of 368 
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pleiotropy, since all intercepts were zero or very close to zero and non-significant(32). We 369 
therefore assume that our results are not biased by pleiotropy.  370 
  In summary, we found no evidence that reproductive aging is causally associated with 371 
CHD and CHD risk factors in women, nor in men. The association between early menopause and 372 
CHD risk in observational studies might be the result of residual confounding, reversed 373 
causation, or reflect a shared aetiology that results in both earlier menopause and higher CHD 374 
risk.     375 
 376 
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